GPX4 and osteoporosis: Deferoxamine (DFO), a well-known iron chelator, has been shown to attenuate osteoporosis by modulating the expression of key ferroptosis-related proteins such as GPX4, HMOX1, and SLC7A11 in osteoblasts [84,98].